Ovarian Cancer in the Era of Precision Surgery and Targeted Therapies.

ABSTRACT:

Background

High-grade serous ovarian cancer (HGSC) is the most common and aggressive subtype of ovarian cancer. Despite initial response to platinum-based chemotherapy, most patients relapse. Cytoreductive surgery at relapse has been shown to improve survival in selected patients, but the biological mechanisms underlying recurrence and resistance remain unclear. This study aimed to investigate whether the mutational profile of HGSC changes from diagnosis to relapse, and to evaluate treatment patterns and survival outcomes in a cohort undergoing cytoreductive surgery.

Methods

Sixteen patients with HGSC who underwent cytoreductive surgery at both diagnosis and relapse were included. Matched tumor tissue samples (n = 32) were collected and sequenced using a 501-gene canc

SUBMITTER: Sisman Y 

PROVIDER: S-EPMC12562755 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature